hLL2 (epratuzumab)
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkins Lymphoma
Conditions
Non-Hodgkins Lymphoma
Trial Timeline
Mar 1, 2003 → —
NCT ID
NCT00054834About hLL2 (epratuzumab)
hLL2 (epratuzumab) is a phase 1 stage product being developed by Gilead Sciences for Non-Hodgkins Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00054834. Target conditions include Non-Hodgkins Lymphoma.
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00054834 | Phase 1 | Terminated |
Competing Products
15 competing products in Non-Hodgkins Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acalabrutinib + ACP-319 | AstraZeneca | Phase 1/2 | 32 |
| JBH492 | Novartis | Phase 1 | 21 |
| Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2C | Roche | Phase 1/2 | 36 |
| Obinutuzumab + Glofitamab + Gemcitabine + Oxaliplatin | Roche | Phase 2 | 42 |
| Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab | Amgen | Phase 2 | 35 |
| Velcade + Temsirolimus | Pfizer | Phase 2 | 35 |
| alemtuzumab | Sanofi | Phase 1/2 | 24 |
| Odronextamab + REGN5837 | Regeneron Pharmaceuticals | Phase 1 | 36 |
| Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine | Bayer | Phase 1/2 | 25 |
| Rituximab + Fludarabine + CAMPTH-1H | Bayer | Phase 2 | 32 |
| Rituximab + CHOP + CVP + Ibritumomab Tiuxetan | Biogen | Phase 2 | 32 |
| Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y Zevalin | Biogen | Phase 2 | 32 |
| Ublituximab | TG Therapeutics | Phase 1/2 | 29 |
| Ublituximab + Lenalidomide | TG Therapeutics | Phase 1 | 18 |
| XmAb13676 | Xencor | Phase 1 | 23 |